Male Infertility: Hormones That Map the Testicular Axis

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Blood testing for male infertility measures testosterone, SHBG, FAI, LH, and FSH to map the hypothalamic–pituitary–testicular axis and pinpoint whether the fertility bottleneck lies in the brain's signaling or testicular output. Fertility is associated with mid-to-upper testosterone and FAI, mid-range SHBG, and low-to-mid LH/FSH when feedback is intact; very high FSH with low testosterone may indicate impaired spermatogenesis.

Read more →

Understand what your hormone testing results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Male infertility and the hormones that map it

Blood biomarkers for male infertility act like a dashboard for the body’s sperm‑making machinery. They show whether the brain is sending the right signals to the testes and whether the testes are responding, helping distinguish signaling problems from factory problems. Hormones outline the chain of command that drives sperm production (spermatogenesis) and sexual function: brain and pituitary messengers (gonadotropin‑releasing hormone, FSH, LH), testicular outputs (testosterone), and modulators that can disrupt the loop (prolactin, estradiol, thyroid hormones). Markers from the testicular support cells (Sertoli and Leydig), especially those tied to germ cell activity (inhibin B), reflect how well the sperm‑forming tissue is working. Blood can also carry genetic clues (karyotype changes, Y‑chromosome microdeletions) that explain severely low or absent sperm and shape realistic treatment options. Together, these biomarkers translate complex physiology into actionable insights—clarifying where the system is off track, guiding targeted therapies or procedures, and revealing when infertility is a sign of broader health issues in the metabolic, endocrine, or inflammatory realms (hypothalamic–pituitary–gonadal axis).

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why hormones matter in a fertility workup

Blood tests for male infertility map how the brain–pituitary–testis axis is working and how much bioactive androgen reaches tissues. Testosterone drives libido, erections, muscle, bone, mood, and—inside the testes—sperm production. SHBG is the carrier protein that controls how much testosterone is “free.” The free androgen index (FAI) estimates that bioavailable pool. LH and FSH are the pituitary signals that tell Leydig and Sertoli cells to make testosterone and support spermatogenesis. In adult men, fertility tends to align with total testosterone in the mid-to-upper reference range, SHBG in the middle, and FAI in the mid-to-upper range. Efficient feedback usually places LH and FSH in the low-to-mid normal range. Very high FSH or LH suggests the testes are underperforming despite strong signaling; very low LH/FSH points to a central (hypothalamic–pituitary) issue. Markedly high testosterone with suppressed LH/FSH raises concern for exogenous androgens, which can shut down sperm production. When testosterone or FAI sits low—either from reduced testicular output or from SHBG being too high—men may notice reduced libido, erectile difficulty, low energy, depressed mood, loss of muscle, and lower sperm counts. Elevated FSH often accompanies damaged seminiferous tubules and poor sperm parameters; low FSH/LH reflects inadequate pituitary drive. In teens, these patterns can show as delayed or blunted puberty; with aging, SHBG often rises, lowering the bioavailable fraction. Big picture, these hormones connect reproductive capacity with metabolic health, bone density, thyroid and liver function, and even cardiovascular risk. Reading testosterone, SHBG, FAI, LH, and FSH together clarifies where the bottleneck lies and what it implies for long-term vitality beyond fertility.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What the hormone panel adds to a fertility workup

Male infertility blood testing provides a window into the hormonal systems that govern not only reproductive capacity but also broader aspects of health, including energy, metabolism, muscle mass, mood, and cardiovascular function. At Superpower, we assess key biomarkers—Testosterone, sex hormone binding globulin (SHBG), free androgen index (FAI), luteinizing hormone (LH), and follicle stimulating hormone (FSH)—to build a clear picture of the hormonal environment influencing male fertility. Testosterone is the principal male sex hormone, essential for sperm production, libido, and the maintenance of muscle and bone mass. SHBG is a protein that binds testosterone, regulating how much is available for the body to use. The free androgen index (FAI) estimates the proportion of testosterone not bound to SHBG, reflecting the biologically active fraction. LH and FSH are pituitary hormones that signal the testes to produce testosterone and support sperm development, respectively. Disruptions in any of these markers can signal issues in the hypothalamic-pituitary-gonadal axis, the system that coordinates reproductive hormone production. Balanced levels of these hormones are crucial for stable reproductive function. Low testosterone or FAI, high or low SHBG, or abnormal LH and FSH can indicate problems with hormone production, regulation, or testicular function, all of which can impact fertility and overall health stability. Interpretation of these biomarkers depends on factors such as age, acute or chronic illness, certain medications, and laboratory assay differences. These variables can influence hormone levels and should be considered when evaluating results.

Frequently Asked Questions

References

  1. Agarwal A, Baskaran S, Parekh N, Cho CL, Henkel R, Vij S, Arafa M, Panner Selvam MK, Shah R (2021). Male infertility. *Lancet*, *397*(10271), 319-333. https://doi.org/10.1016/S0140-6736(20)32667-2
  2. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*, *103*(5), 1715-1744. https://doi.org/10.1210/jc.2018-00229
  3. Basaria S (2014). Male hypogonadism. *Lancet*, *383*(9924), 1250-1263. https://doi.org/10.1016/S0140-6736(13)61126-5
  4. Centola GM (2014). Semen assessment. *Urologic Clinics of North America*, *41*(1), 163-167. https://doi.org/10.1016/j.ucl.2013.08.007
  5. Centers for Disease Control and Prevention. (2024). *Infertility FAQs*. https://www.cdc.gov/reproductive-health/infertility-faq/index.html

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey